Please assess the completion status of the following clinical trial:

Trial Title: Empirical Versus Preemptive Antifungal Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)~  * Newly diagnosed disease or disease in first relapse after hematological remission lasting for a minimum of 6 months AND meets one of the following criteria:~    * Starting remission-induction chemotherapy within 3 days prior to study randomization~   * Starting myeloablative conditioning regimen to prepare for a first allogeneic hematopoietic stem cell transplantation within 3 days prior to study randomization~* Planning a hospital admission for the duration of the neutropenic phase (ANC \< 0.5 x 10\^9 /L)~* Planning to receive oral or intravenous fluconazole for Candida prophylaxis at a dose of 400 mg/day~  * Fluconazole is discontinued during caspofungin acetate administration~* No previous or current history of proven or probable invasive fungal disease (IFD)~PATIENT CHARACTERISTICS:~* See Disease Characteristics~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients muse use effective contraception during and for at least 3 months after completion of study therapy~* No current clinical diagnosis of pneumonia~* No serious, uncontrolled, concomitant disease or comorbidity that, in the opinion of the investigator, may compromise adherence to the study protocol~* No history of allergy or any adverse reaction to echinocandin drugs (i.e., caspofungin acetate, micafungin, or anidulafungin)~* No hypersensitivity to caspofungin active substance or to any of the excipients~* No inadequately treated infection~* No documented HIV infection~* No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule~* No history of liver cirrhosis or severe hepatic insufficiency (i.e., Child Pugh Class C, D, or E)~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No concurrent participation on another clinical trial using an investigational drug for infectious diseases~* No other concurrent systemic antifungal therapy (oral or intravenous)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empirical (Type: ACTIVE_COMPARATOR): Empirical approach (fever driven) for starting antifungal therapy
- Pre-emptive (Type: EXPERIMENTAL): Pre-emptive approach (diagnostic driven) for starting antifungal therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).